Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02593877
Other study ID # 010770
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 1, 2016
Est. completion date July 30, 2018

Study information

Verified date August 2018
Source Queen Mary University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial compares the haemostatic effect of viscoelastic haemostatic assay (VHA)-guided transfusion strategy versus non-VHA guided transfusion strategy in haemorrhaging trauma patients. Half of the randomised patients will receive VHA-led management of bleeding, whilst the other half will receive massive transfusion protocol resuscitation using conventional coagulation tests.


Description:

Trauma is the most frequent cause of death in persons aged under 40, with half of these deaths resulting from uncontrolled bleeding. 1 in 4 of all severely injured and shocked patients develop a clotting abnormality termed Trauma Induced Coagulopathy (TIC) within minutes of injury, which causes blood to continue being lost from the body faster than it can be stemmed. Many more injured patients will go on to develop different types of coagulopathy at different times during the course of their treatment, either as a result of their body's ongoing response to trauma or as a consequence of their clinical care. Ultimately coagulopathic patients have increased blood transfusion requirements and suffer more adverse outcomes (e.g. multi organ failure).

Current management of coagulopathic, haemorrhaging trauma patients comprises the unguided transfusion of large volumes of red blood cells and clotting product supplements. Without rapidly available and validated diagnostics, products are delivered empirically to patients blind to the type and severity of TIC they may have or indeed even if they do not have TIC. This study will compare outcomes of viscoelastic haemostatic assay (VHA)-guided resuscitation versus conventional management of critically bleeding trauma patients. The hypothesis is that goal-directed haemostatic resuscitation of coagulopathic bleeding trauma patients will yield improved outcomes and reduced blood product demand, compared to empiric massive transfusion therapy.


Recruitment information / eligibility

Status Completed
Enrollment 412
Est. completion date July 30, 2018
Est. primary completion date July 3, 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

Adult trauma patients (according to local definitions) will be enrolled if they:

- Present with hemorrhagic shock at any time from the time of injury until admission to the emergency department (where shock is defined by HR>100 b/min and/or systolic BP<90 mmHg) AND activate the local massive transfusion protocol

- Randomized within 3 hours of injury and 1 hour of admission to the emergency department

- Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (e.g.trauma team leader)

Exclusion Criteria:

- Any inclusion criteria are not met

Study Design


Intervention

Device:
VHA algorithm
Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)

Locations

Country Name City State
Denmark Copenhagen University Hospital Copenhagen
Germany Kliniken der Stadt Köln gGmbH Cologne
Netherlands Academic Medical Centre Amsterdam
Norway Oslo University Hospital Oslo
United Kingdom The Royal London Hospital London Greater London
United Kingdom Queens Medical Centre Nottingham
United Kingdom John Radcliffe Hospital Oxford

Sponsors (8)

Lead Sponsor Collaborator
Queen Mary University of London Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Barts & The London NHS Trust, European Commission, Klinikum der Universität Köln, Oslo University Hospital, Oxford University Hospitals NHS Trust, Rigshospitalet, Denmark

Countries where clinical trial is conducted

Denmark,  Germany,  Netherlands,  Norway,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects alive and free of massive transfusion Proportion of subjects at 24 hours post-admission who are alive and free of massive transfusion (i.e. received 10 or more units of red blood cells within 24 hours) 24 hours
Secondary 6hr Mortality All-cause mortality at 6-hours post admission 6 hours
Secondary 24hr Mortality All-cause mortality at 24-hours post admission 24 hours
Secondary 28d Mortality All-cause mortality at 28-days post admission 28-days
Secondary 90d Mortality All-cause mortality at 90-days post admission 90-days
Secondary Duration of coagulopathy The time spent in coagulopathic state, as defined by Prothrombin Time / International Ratio (PTr) PTr >1.2) from Admission until the point of hemostasis (itself defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved). 28-days post admission
Secondary Severity of coagulopathy Defined by the area under the Prothrombin Time / International Ratio (PTr) curve from Admission to the point of haemostasis (where time of hemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved). 28-days post admission
Secondary Proportion of patients with corrected coagulopathy after first 8U RBC Proportion of patients with corrected coagulopathy after first 8U RBC 28-days post admission
Secondary Time to hemostasis Time from Admission to the point of hemostasis (where time of hemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved). 28-days post admission
Secondary Time spent in coagulopathic condition until haemostasis Time of haemostasis is defined the period from Admission to the point as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved. Coagulopathy defined as PTr >1.2. 28-days post admission
Secondary 6hr Blood products transfused Total blood products (RBC, plasma, platelets alone and in total) transfused in first 6hours after admission 6 hours
Secondary 24hr Blood products transfused Total blood products (RBC, plasma, platelets alone and in total) transfused in first 24hours after admission 24 hours
Secondary 28d Ventilator-free days Calculated by the subtracting the number of days spent on mechanical ventilation from 28. 28 days
Secondary 28d ICU-free days Calculated by the subtracting the number of days spent on intensive care unit from 28. 28 days
Secondary Length of stay Length of stay will be recorded in days, for the total number spent in ICU and in Hospital. If the patient is in the hospital at any time point during a day, this day will be considered a hospital day. 28 days
Secondary Symptomatic thromboembolic events Symptomatic venous thromboembolic events shall be recorded, as confirmed by radiology. Other thromboembolic events such as myocardial infarction and/or stroke shall be identified by standard clinical diagnostic investigation(s). 28 days
Secondary Transfusion-related complications Incidence, category and severity of acute transfusion reactions will be defined according to UK SHOT (United Kingdom Serious Hazards of Transfusion) 28-days
Secondary Organ dysfunction Organ dysfunction shall be measured as Sequential Organ Failure Assessment (SOFA) score from admission to day 28 or discharge 28-days
Secondary 28d/discharge QoL Health-Related Quality of Life (HRQoL) will be measured at 28 day post admission or upon discharge if sooner 28 days
Secondary 90d QoL Health-Related Quality of Life (HRQoL) will be measured at 90 day post admission 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4
Completed NCT01210417 - Trauma Heart to Arm Time N/A